Page 95 - Read Online

Page 6 of 6 Bellentani. Hepatoma Res 2020;6:29 I http://dx.doi.org/10.20517/2394-5079.2020.10

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017;37:81-4.
2. Bellentani S, Baroni GS, Piscaglia F, Tiribelli C. Natural history of nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Clin
Liver Dis (Hoboken) 2016;8:105-7.
3. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic
fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.
4. Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH.
Hepatology 2019;70:1885-8.
5. Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci 2016;61:1226-33.
6. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, et al. Modeling NAFLD disease burden in China, France, Germany, Italy,
Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
7. Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, et al. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
Swiss Med Wkly 2019;149:w20152.
8. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al.; Global Burden of Disease Cancer Collaboration. Global, regional,
and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer
groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48.
9. Bellentani S, Saccoccio G, Masutti F, Giacca M, Miglioli L, et al. Risk factors for alcoholic liver disease. Addict Biol 2000;5:261-8.
10. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the
Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
11. Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, et al. Microbiota, NASH, HCC and the potential role of probiotics.
Carcinogenesis 2017;38:231-40.
12. Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell
2018;175:1289-306.e1220.
13. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association
for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver
disease. J Hepatol 2016;64:1388-402.
14. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease:
practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
15. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic
assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
16. Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and
identification of research gaps. Hepatology 2019;70:1457-69.
17. Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, et al. Lipid metabolic reprogramming in hepatocellular carcinoma. Cancers
(Basel) 2018;10:447.
18. Gomes AL, Teijeiro A, Buren S, Tummala KS, Yilmaz M, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic
steatohepatitis and hepatocellular carcinoma. Cancer Cell 2016;30:161-75.
19. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through
senescence secretome. Nature 2013;499:97-101.
20. Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-
mediated suppression of antitumor immunity. Cancer Discov 2017;7:522-38.
21. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. Expanding the natural history of nonalcoholic steatohepatitis: from
cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
22. Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in
patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology 2020;71:907-16.
23. Unalp-Arida A, Ruhl CE. PNPLA3 I148M and liver fat and fibrosis scores predict liver disease mortality in the United States population.
Hepatology 2020;71:820-34.
24. Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in
patients with nonalcoholic fatty liver disease: expert review. Gastroenterology 2020; Epub ahead of print. doi: 10.1053/j.gastro.2019.12.053
25. Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol 2018;68:326-34.
26. Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, et al. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in
the Veterans Health Administration. Aliment Pharmacol Ther 2018;47:268-78.
27. Reig M, Gambato M, Man NK, Roberts JP, Victor D, et al. Should patients with NAFLD/NASH be surveyed for HCC? Transplantation
2019;103:39-44.